Generation Bio Co. (GBIO)
| Market Cap | 308.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -128.59M |
| Shares Out | 57.09M |
| EPS (ttm) | -2.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 318,133 |
| Open | 5.19 |
| Previous Close | 5.14 |
| Day's Range | 4.99 - 5.44 |
| 52-Week Range | 3.96 - 35.41 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 22.70 (+319.6%) |
| Earnings Date | May 11, 2022 |
About GBIO
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for GBIO stock is "Buy." The 12-month stock price forecast is 22.7, which is an increase of 319.59% from the latest price.
News
Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results
Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines
Generation Bio to Participate in 21st Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...
Generation Bio Co. (GBIO) Upgraded to Buy: Here's Why
Generation Bio Co. (GBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Generation Bio Co. (GBIO)? Wall Street Analysts Think 505%
The consensus price target hints at a 504.9% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
Generation Bio to Participate in 42nd Annual Cowen Health Care Conference
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...
Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024 Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024
Generation Bio Promotes Antoinette Paone, M.S., MBA to Chief Operating Officer
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Generation Bio Co. - GBIO
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Generation Bio Co. ("Generation" or the "Company") (NASDAQ: GBIO). Such investors are advised to co...
Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...
SHAREHOLDER ALERT: Robbins LLP Investigates Generation Bio Co. (GBIO) on Behalf of Shareholders
SAN DIEGO--(BUSINESS WIRE)---- $GBIO #classaction--Generation Bio Co. (GBIO) Reports Poor Results for Preclinical Studies for Hemophilia A Program
Generation Bio Hits 52-Week Low After Preclinical Data From Hemophilia A Program
Generation Bio Co (NASDAQ: GBIO) provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A and an update on its development non-vi...
Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program
CAMBRIDGE, MASS., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today prov...
Generation Bio Reports Business Highlights and Third Quarter 2021 Financial Results
New preclinical retinal data illustrating potential for expansive therapeutic applications of ctLNP delivery presented at ESGCT 2021 Annual Virtual Congress New preclinical retinal data illustrating pot...
Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Toler...
Sub-retinal delivery of closed-ended DNA (ceDNA) using a retina-specific cell-targeted LNP (ctLNP) demonstrated broad photoreceptor distribution, durable expression and tolerability in rodents; potentia...
Generation Bio to Present at Jefferies Virtual Gene Therapy/Editing Summit
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...
Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress
CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today anno...
Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported r...
Generation Bio to Present at Wedbush PacGrow Healthcare Conference 2021
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Pro...
Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing
Generation Bio to Present at William Blair Biotech Focus Conference
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff ...
Generation Bio to Present at the JMP Securities Life Sciences Conference
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff ...
Generation Bio to Present at the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff M...
Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports ...
Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model
Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced three digi...